Antibiotics: Market Research Report

Date: October 22, 2010
Pages: 850
Price:
US$ 4,500.00
Publisher: Global Industry Analysts, Inc
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: AFA7C48253EEN
Leaflet:

Download PDF Leaflet

Antibiotics: Market Research Report
This report analyzes the worldwide markets for Antibiotics in US$ Million by the following product segments: Penicillin, Cephalosporins, Macrolides, Quinolones, Carbapenems, and Other Antibiotics (Aminoglycosides, Tetracyclines, Sulfonamides, Mupirocin, Glycopeptides, Synercid, and Oxazolidinones).

The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia Pacific, and Rest of World.

Annual estimates and forecasts are provided for the period 2007 through 2015.

A seven-year historic analysis is also provided for these markets.

The report profiles 197 companies including many key and niche players such as Abbott Laboratories, Astellas Pharma, Inc., Bayer HealthCare AG, Bristol-Myers Squibb Co., Cubist Pharmaceuticals, Inc., Daiichi Sankyo Company, Limited, Eli Lilly and Co., GlaxoSmithKline Plc, Johnson & Johnson, Kyorin Pharmaceutical Co., Ltd., LG Life Sciences Limited, MiddleBrook™ Pharmaceuticals, Inc., Novartis AG, Pfizer Inc., Pliva d.d., Roche, Sanofi-Aventis SA, Takeda Pharmaceutical Company, Ltd., and Toyama Chemical Co., Ltd.

Market data and analytics are derived from primary and secondary research.

Company profiles are mostly extracted from URL research and reported select online sources.
1.INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations
Disclaimers
Data Interpretation & Reporting Level
Quantitative Techniques & Analytics
Product Definitions and Scope of Study
Penicillin
Cephalosporins
Macrolides
Quinolones
Carbapenems
Other Antibiotics
Aminoglycosides
Tetracyclines
Sulfonamides
Mupirocin
Glycopeptides
Synercid
Oxazolidinones
Linezolid

2.INDUSTRY OVERVIEW

Antibiotic Resistance and Generic Competition to Impact Long Term Growth
New Regulations Guiding Usage of Drugs to Drive Growth
Current & Future Analysis

3.MARKET DYNAMICS

Anti-Bacterials Segment Drives Global Anti- Infectives Market
Antibiotic Resistance – A Primary Growth Inhibitor
Antibiotic-Resistant Bacteria by Type
Patent Expiries Commoditize Antibiotics
Patent Expiries of Leading Drugs in the Recent Past, Current, and Future (2000 –2013)
Anti-MRSA Antibiotics Find Their Way

Table 1. World MRSA Treatments (2007 & 2008) : Percentage Share Breakdown by Leading Antibiotic Drugs -Vancomycin, Zyvox, Cubicin and Tygacil (includes corresponding Graph/Chart)

Key Antibiotics in Pipeline

4.COMPETITION

Highly Competitive Market

Table 2. Leading Players in the Worldwide Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Glaxo Smithkline, Sanofi-aventis, Johnson & Johnson, Bayer, Abbott, Wyeth, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline – The Undisputed Leader of Penicillin Market

Table 3. Worldwide Leading Antibiotics within Penicillin Class (2005 & 2006): Percentage Breakdown by Value for Augmentin, Zosyn/Tazocin, Amoxil, and Others (includes corresponding Graph/Chart)

GlaxoSmithKline Leads Cephalosporin Market

Table 4. Worldwide Leading Antibiotics within Cephalosporin Class (2005 & 2006): Percentage Breakdown by Value for Rocephin, Ceftin/Zinnat, Flomox, Fortum/Fortaz, Cefzil, Cefzon, Flumarin, and Others (includes corresponding Graph/Chart)

Pfizer Dominates Macrolides Market

Table 5. Worldwide Leading Antibiotics within Macrolide Class (2005 & 2006): Percentage Breakdown by Value for Zithromax, Klaricid/Biaxin, Ketek, and Others (includes corresponding Graph/Chart)

Levaquin/Tavanic – The Most Preferred Quinolone Antibiotic

Table 6. Worldwide Leading Antibiotics within Quinolone Class (2005 & 2006): Percentage Breakdown by Value for Levaquin/Tavanic, Avelox, Ciprobay/Ciproxin, Cravid, and Others (includes corresponding Graph/Chart)

Merck Rules Carbapenems Market

Table 7. Worldwide Leading Antibiotics within Carbapenem Class (2005 & 2006): Percentage Breakdown by Value for Primaxin, Merrem, Invanz, and Others (includes corresponding Graph/Chart)

5.PRODUCT OVERVIEW

Antibiotics – An Introduction
Antibiotic Resistance
b–Lactams
Classification of Antibiotics
Key Milestones in Antibiotic Development
Antibiotic Types
Penicillin
History
About the Drug
Cephalosporins
Treatment
Effects of the Drug
Macrolides
Treatment
Quinolones

Table 8. Leading Global Ciprofloxacin Brands: (2006-2008) (includes corresponding Graph/Chart)

Carbapenems
Other Antibiotics
Aminoglycosides
Treatment
Effects of the Drug
Tetracyclines
Treatment
Effects of the Drug
Sulfonamides
Treatment
Effects of the Drug
Mupirocin
Glycopeptides
Synercid
Oxazolidinones
Linezolid

6.RESEARCH FINDINGS

New Design for Monitoring Toxin Delivery Activity of Pathogenic Bacteria
Cephalosporins Effective when Compared to Penicillin
FDA Bans Baytril Antibiotic for Chickens
Erythromycin Along with Some Specific Drugs Increase Risk of Sudden Death
Rise in Usage of Quinolones for Urinary Tract Infections Leads to Drug Resistance
Polyphor Discovers POL7080 - New Antibiotic Against Gram-Negative Bacteria

7.FDA APPROVALS/PATENTS

MiddleBrook Obtains NDA Approval for MOXATAG™
J&JPRD Seeks FDA Approval for Doripenem Antibiotic
J&JPRD Seeks FDA Approval for Investigational Antibiotic, Ceftobiprole
GSK Receives Approval for ALTARGO® in Europe
APL Receives FDA Approval for Cefpodoxime Proxetil
Cubist Receives Approval to Market CUBICIN in Canada
Cubist Obtains Approval to Market CUBICIN for Added Indications in EU
Cubist Gains Approval for CUBICIN in Taiwan and South Korea
Cethromycin Achieves FDA’s Orphan Drug Designation
FDA Approves Wockhardt’s Cefotaxime Injection
FDA Approves Doxycycline Tablets
FDA Approves Clarithromycin
FDA Approves Doxycycline Tablets For The US Market
Johnson & Johnson Applies Doripenem For FDA Approval
FDA Certifies Antibioticos do Brasil’s Plant
FDA Certifies ANDA For Cefdinir Capsules
US FDA Approves Teva’s Cefprozil Tablets
FDA Certifies ANDA for Cephalexin Capsules
American Pharmaceutical Partners Receives FDA Approvals for Ceftriaxone for Injection, USP
Advancis’s Keflex Receives FDA Approval
Wockhardt Gains Marketing Approval for Cefuroxime axetil in the US
Wyeth’s Mylotarq Receives Government’s Approval
FDA Approves Generic Version of Zithromax
Pfizer Wins FDA Approval for Zmax™
Venus Remedies Files Second PCT for New Cephalosporins
Falcon Gains US FDA Approval for its Generic Anti-Infective Solution
Cadilla Receives FDA Approval to Market Clindamycin

8.RECENT INDUSTRY ACTIVITY

DSM Opens Eco-friendly Antibiotics Plant ZOR-f, in the Netherlands
Daiichi Leverages Ranbaxy’s Network to Market Tavanic in South Africa and Romania
Pfizer Acquires Wyeth
Durata Therapeutics Acquires Pfizer’s Vicuron Pharmaceuticals
Cubist Completes Acquisition of Calixa Therapeutics
AstraZeneca to Acquire Novexel
Tianyin and Sichuan Mingxin to Establish an Antibiotic Joint Venture
Pfizer and Aurobindo Pharma Ink Agreement for Producing Off Patent Drugs
BMP Sunstone to Acquire Majority Stake in Zhangjiakou Shengda
Novartis to Take Over Protez Pharmaceuticals

3I TO BUY ALPHARMA UNIT

NCPC to Acquire Stake in DSM’s Antibiotics Division
ULL Establishes New Antibiotics Unit in Himachal Pradesh
Biocat to Expand Presence in the Indian Market
PRWT Acquires Cherokee Chemical Unit from Merck
CSPC Joins Hands with Indonesian Firms

9.STRATEGIC CORPORATE DEVELOPMENTS IN THE RECENT PAST – A PERSPECTIVE BUILDER

Nisshin-Kyorin to Merge with Kyorin Pharmaceutical
Schering-Plough Acquires Organon BioSciences
GSK & Anacor Partner for Boron Chemistry-Based Antibiotics and Antivirals
Iroko Bags Canadian Rights to Vancocin®
Cubist Licenses CUBICIN Rights to Merck
Sagent Partners with Astral to Develop Injectable Antibiotics
MR Healthcare to Manufacture New Antibiotics & Medicines
Livzon Synthetic to Acquire Antibiotic Intermediate from Jiaozuo
C&O Pharmaceutical to Distribute Meiact in China
Bioton Signs Deal to Market Antibiotics in Russia
Toyama Gains Marketing Approval for Geninax® in Japan
Forest Laboratories Acquires Cerexa
Oscient Modifies Licensing Agreement With LG Life Sciences
Orchid Sign Licensing & Distribution Pact With Actavis
Forest Laboratories Revokes Partnership With Replidyne
SRI and Blanca Collaborate To Develop & Test Carbacephem
AstraZeneca To Expand Research Center For Antibiotics
Jade Pharmaceutical Begins Levofloxacin’s Production in China
Reyoung To Start Antibiotic Production At New Facility
Toyama Begins T-705 Clinical Trials
SmPC For Sanofi-Aventis’ Ketek® Updated
Lupin Receives Approval for Cefpodoxime Proxetil Antiobiotic Tablets in France
Antibiotice Plans To Infuse Funds For Antibiotics Production
UAE Approves Pfizer’s Zithromax SD

10.PRODUCT INNOVATIONS/INTRODUCTIONS

Janssen-Cilag Launches Doribax™ - New Carbapenem Antibiotic
MIT Scientists Develop a New Antibiotic, Rhodostreptomycin
Watson Pharma Introduces Biaxin XL’s Generic Version

11.PRODUCT INNOVATIONS IN THE RECENT PAST – A PERSPECTIVE BUILDER

Toyama Launches New Garenoxacin Quinolone Antibiotic
Wockhardt to Introduce Cefprozil in the US
MSD India Launches Invanza in India
Orchid Chemicals to Introduce Three New Drugs in the US
DUSA Pharmaceuticals Releases ClindaReach™
Mylan Releases Cipro’s Generic Version
Macrolide Antibiotic Developed In the US
University of Michigan Devises NMR Spectroscopy For Antibiotics
Glycopeptide-Cephalosporin Antibiotics Developed In The US
Neosil Tests NEO 101 Antibiotic
New Antibiotic Developed By Canadian Inventors
Abbott Canada Releases FACTIVE® Antibiotic Tablets In Canada
Penicillin Binding Protein Found In Japan
Venus Remedies Releases Mucomelt-Forte

12.FOCUS ON SELECT GLOBAL PLAYERS

Abbott Laboratories (USA)
Astellas Pharma, Inc. (Japan)
Bayer HealthCare AG (Germany)
Bristol-Myers Squibb Co. (USA)
Cubist Pharmaceuticals, Inc. (USA)
Daiichi Sankyo Company, Limited (Japan)
Eli Lilly and Co. (USA)
GlaxoSmithKline Plc (UK)
Johnson & Johnson (USA)
Kyorin Pharmaceutical Co., Ltd. (Japan)
LG Life Sciences Limited (Korea)
MiddleBrook™ Pharmaceuticals, Inc. (USA)
Novartis AG (Switzerland)
Pfizer Inc. (USA)
Pliva d.d. (Croatia)
Roche (Switzerland)
Sanofi-Aventis SA (France)
Takeda Pharmaceutical Company, Ltd. (Japan)
Toyama Chemical Co., Ltd. (Japan)

13.GLOBAL MARKET PERSPECTIVE

Table 9. World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 10. World Historic Review for Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 11. World 11-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 12. World Recent Past, Current & Future Analysis for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 13. World Historic Review for Penicillin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 14. World 11-Year Perspective for Penicillin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 15. World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 16. World Historic Review for Cephalosporin by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 17. World 11-Year Perspective for Cephalosporin by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 18. World Recent Past, Current & Future Analysis for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 19. World Historic Review for Macrolides by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 20. World 11-Year Perspective for Macrolides by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 21. World Recent Past, Current & Future Analysis for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 22. World Historic Review for Quinolones by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 23. World 11-Year Perspective for Quinolones by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 24. World Recent Past, Current & Future Analysis for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 25. World Historic Review for Carbapenems by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 26. World 11-Year Perspective for Carbapenems by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 27. World Recent Past, Current & Future Analysis for Other Antibiotics by Geographic Region – US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 28. World Historic Review for Other Antibiotics by Geographic Region – US, Canada, Jap an, Europe, Asia- Pacific (excluding Japan), and Rest of World Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 29. World 11-Year Perspective for Other Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan), and Rest of World Markets for Years 2005, 2010 & 2015 (includes corresponding Graph/Chart)

14.THE UNITED STATES

A. MARKET ANALYSIS

Current and Future Analysis
Antibiotics Approved Between 2000 and 2005 in the United States
Competition

Table 30. Leading Players in the US Antibiotics Market (2008): Percentage Breakdown by Value Sales for Pfizer, Johnson & Johnson, GlaxoSmithKline, Abbott, and Others (includes corresponding Graph/Chart)

Key Players

B. MARKET ANALYTICS

Table 31. US Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 32. US Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics MarketsIndependently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 33. US 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

15.CANADA

A. MARKET ANALYSIS

Current And Future Analysis

B. MARKET ANALYTICS

Table 34. Canadian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 35. Canadian Historic Review for Antibiotics by Product Segment – Penicillin,Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 36. Canadian 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

16.JAPAN

A. MARKET ANALYSIS

Current and Future Analysis
Key Players

B. MARKET ANALYTICS

Table 37. Japanese Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 38. Japanese Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 39. Japanese 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17.EUROPE

A. MARKET ANALYSIS

Current and Future Analysis

B. MARKET ANALYTICS

Table 40. European Recent Past, Current & Future Analysis for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 41. European Historic Review for Antibiotics by Geographic Region – France, Germany, Italy, UK, Spain, and Rest of Europe Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 42. European Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 43. European Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems, and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 44. European 11-Year Perspective for Antibiotics by Geographic Region – Percentage Breakdown of Dollar Sales for France, Germany, Italy, UK, Spain, and Rest of Europe Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)
Table 45. European 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems, and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17A.FRANCE

A. MARKET ANALYSIS

Current and Future Analysis
Trends
Over Consumption of Antibiotics – Cause of Concern
Sanofi-Aventis SA – A Key Player

B. MARKET ANALYTICS

Table 46. French Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 47. French Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 48. French 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & 2015 (includes corresponding Graph/Chart)

17B.GERMANY

A. MARKET ANALYSIS

Current and Future Analysis
Bayer HealthCare AG – A Key Player

B. MARKET ANALYTICS

Table 49. German Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 50. German Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 51. German 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17C.ITALY

A. MARKET ANALYSIS

Current and Future Analysis

B. MARKET ANALYTICS

Table 52. Italian Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 53. Italian Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 54. Italian 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17D.THE UNITED KINGDOM

A. MARKET ANALYSIS

Current And Future Analysis
GlaxoSmithKline Plc – A Key Player

B. MARKET ANALYTICS

Table 55. UK Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 56. UK Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, acrolides, Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 57. UK 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for2005, 2010 & 2015 (includes corresponding Graph/Chart)

17E.SPAIN

Market Analysis

Table 58. Spanish Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 59. Spanish Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 60. Spanish 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

17F.REST OF EUROPE

A. MARKET ANALYSIS

Current and Future Analysis
Poland

Table 61. Polish Market for Antibiotics (2008): Percentage Breakdown of Market Share by Leading Companies – GSK Pharma, Bioton, Sandoz Corp, Ranbaxy and Others (includes corresponding Graph/Chart)

Focus On Select Players

B. MARKET ANALYTICS

Table 62. Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 63. Rest of Europe Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 64. Rest of Europe 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

18.ASIA-PACIFIC

A. MARKET ANALYSIS

Current and Future Analysis
India
Rising Prices of Penicillin G to Affect Antibiotics Production
Market for Injectable Antibiotics Poised to Grow
Cipla, Pharmaceutical Market Leader in 2009
China
Carbapenem Witnesses Robust Growth in China
Key Players
Ranbaxy Laboratories Ltd. (India)

B. MARKET ANALYTICS

Table 65. Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 66. Asia-Pacific Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 67. Asia-Pacific 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides, Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

19.REST OF WORLD

A. MARKET ANALYSIS

Current and Future Analysis

B. MARKET ANALYTICS

Table 68. Rest of World Recent Past, Current & Future Analysis for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2007 through 2015 (includes corresponding Graph/Chart)
Table 69. Rest of World Historic Review for Antibiotics by Product Segment – Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets Independently Analyzed with Annual Sales in US$ Million for Years 2000 through 2006 (includes corresponding Graph/Chart)
Table 70. Rest of World 11-Year Perspective for Antibiotics by Product Segment – Percentage Breakdown of Dollar Sales for Penicillin, Cephalosporin, Macrolides,Quinolones, Carbapenems and Other Antibiotics Markets for 2005, 2010 & 2015 (includes corresponding Graph/Chart)

Competition
Total Companies Profiled: 197 (including Divisions/Subsidiaries - 238)
Region/CountryPlayers
The United States
Canada
Japan
Europe
France
Germany
The United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific (Excluding Japan)
Middle East
Latin America
Africa
Skip to top


Ask Your Question

Antibiotics: Market Research Report
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: